Skip to content

Study · Animal study (in vivo) · rabbit · 1996

3 results

Thymosin alpha 1 protects liver and aorta from oxidative damage in atherosclerotic rabbits.

Gökkusu C, Ademoğlu E, Türkoğlu UM, Oz H, Oz F

Life sciences1 Jan 1996Cited by 16 (Europe PMC)

PMID8809225 (opens in a new tab)DOI10.1016/0024-3205(96)00421-3 (opens in a new tab)PepBankPUB-08809225
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In atherosclerotic rabbits, thymosin alpha‑1 treatment was reported to normalize changed lipid levels.

    In plain wordsIn atherosclerotic rabbits, thymosin alpha‑1 appeared to bring altered fat levels back toward normal.

    Peptide
    Thymosin alpha-1
    Outcome
    Direction not reportedPlasma, liver and aorta lipid levels
    Study

    rabbitn: not reported in source

    atherosclerotic rabbits
    Outcome group
    Lipids · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Our results demonstrated that thymosin alpha 1 might normalize changed lipid levels and increased lipid peroxides and also elevate decreased GSH in the plasma, liver and aorta tissues of atherosclerotic rabbits.
    1 context sentence
    Summary · context
    In the present study, we have examined the effects of thymosin alpha 1 on lipid levels and lipid peroxidation and glutathione (GSH) content in the plasma, liver and aorta tissues of atherosclerotic rabbits.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In atherosclerotic rabbits, thymosin alpha‑1 treatment was reported to normalize increased lipid peroxides in plasma, liver and aorta tissues.

    In plain wordsIn atherosclerotic rabbits, thymosin alpha‑1 appeared to lower raised fat-oxidation products in blood, liver and aorta.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseLipid peroxides in plasma, liver and aorta
    Study

    rabbitn: not reported in source

    atherosclerotic rabbits
    Outcome group
    Oxidative stress · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    thymosin alpha 1 might normalize changed lipid levels and increased lipid peroxides and also elevate decreased GSH in the plasma, liver and aorta tissues of atherosclerotic rabbits.
    1 context sentence
    Summary · context
    In the present study, we have examined the effects of thymosin alpha 1 on lipid levels and lipid peroxidation and glutathione (GSH) content in the plasma, liver and aorta tissues of atherosclerotic rabbits.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In atherosclerotic rabbits, thymosin alpha‑1 treatment was reported to raise decreased glutathione (GSH) in plasma, liver and aorta tissues.

    In plain wordsIn atherosclerotic rabbits, thymosin alpha‑1 appeared to raise lowered glutathione, an antioxidant, in blood, liver and aorta.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseGlutathione (GSH) content in plasma, liver and aorta
    Study

    rabbitn: not reported in source

    atherosclerotic rabbits
    Outcome group
    Oxidative stress · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    also elevate decreased GSH in the plasma, liver and aorta tissues of atherosclerotic rabbits.
    1 context sentence
    Summary · context
    In the present study, we have examined the effects of thymosin alpha 1 on lipid levels and lipid peroxidation and glutathione (GSH) content in the plasma, liver and aorta tissues of atherosclerotic rabbits.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.